VinayKumarGudenaMDMPH

Oncology • Greensboro, NC

Breast Cancer, Hematologic Oncology

Medical Director of Cancer Research, Cone Health Cancer Center

Join to view full profile

Dr. Gudena is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gudena's full profile

Already have an account?

Office
2400 W Friendly Ave
Greensboro, NC 27403
Phone+1 336-832-1100

Fax+1 336-832-0795

Education & Training

Medical University of South CarolinaFellowship, Hematology and Medical Oncology, 2006 - 2009
Canton Medical Education Foundation/NEOMEDResidency, Internal Medicine, 2002 - 2006
University of Texas School of Public HealthMPH, Occupational and Environmental Health, 2000 - 2002
Andhra Medical College NTRClass of 2000

Certifications & Licensure

NC State Medical License 2015 - 2025
OH State Medical License 2002 - 2017
SC State Medical License 2007 - 2009
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Master Faculty Ohio University, 2015

Clinical Trials

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer Start of enrollment: 2017 Jan 18
Active, not recruiting
Phase 3

Publications & Presentations

PubMed

2 citations
Efficacy of a Patient Education Session for Cancer Patients Receiving Immunotherapy.
Stephanie M Teixeira-Poit, Katelin Sawicki, Wendy O'Kelley, Myrtle Hardin, Marjorie Jenkins
Seminars in Oncology Nursing. 2023-08-01
42 citations
Statins and Left Ventricular Ejection Fraction Following Doxorubicin Treatment.
W Gregory Hundley, Ralph D'Agostino Jr, Teresa Crotts, Karen Craver, Mary Helen Hackney
NEJM Evidence. 2022-09-01
10 citations
Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer.
Carey K Anders, Mark G Woodcock, Amanda E D Van Swearingen, Dominic T Moore, Maria J Sambade
Journal for Immunotherapy of Cancer. 2022-02-01

Lectures

Performance of Oncotype Dx test in patients with T1bN0, grade 1, hormone receptor-positive, HER2-negative breast cancer.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Breast Cancer: Comet StudyOctober 9th, 2017

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Other Languages

Hindi, Telugu